FDA Alert: TNOX, DNA, NVN, CRDM
When the
FDA speaks, the investment community and companies listen. It
soon will be time for the FDA to meet, speak, and decide the
fate of several new products. An FDA meeting usually means
opportunity for traders to take advantage of volatility
Keep These Biotechs On Your Radar
This weekGÇÖs initial biotech buzz will focus on the FDAGÇÖs
final approval of AstraZencaGÇÖs novel treatment for lung
cancer, an approval that should come today. The drug Iressa
is an entirely new approach to the treatment of cancer, an
approach that other companies are trying to mimic. Last
September
Meeting Alert: Watch These 6 Biotechs
The annual meeting of the American Urological Association
(AUA) officially begins today in Chicago, highlighting new
advances in the treatment of a variety of urological
diseases. This is the major meeting for urologists all over
the world and a meeting that many on Wall Street keep an eye
on.
These Are The 5 Stocks To Watch Ahead Of Major Meeting
On Sunday, March 30, the American College of Cardiology
holds its annual meeting in Chicago. The meeting is a
major forum for cardiologists from around the world to
present data on new drugs to treat all aspects of
cardiovascular
These Results Will Have A Significant Impact
Over the next several weeks, two emerging biotechs will take
center stage when both release experimental drug data from
ongoing pivotal phase III clinical trials. The results
of these trials will have a lasting impact on each companyGÇÖs
long-term financial health. For any biotech, the result of a
phase
FDA Alert: ISTA Pharmaceuticals (ISTA)
On Monday, March 17 the FDAGÇÖs Dermatologic and Ophthalmic
Drugs Advisory Committee will vote on whether to approve the
New Drug Application (NDA) of ISTA PharmaceuticalsGÇÖ (ISTA)
drug Vitrase to treat acute vitreous hemorrhage. The Advisory
Committee
FDA Alert: CryoCath Technologies (TSX: CYAHF)
On Thursday, March 6, the FDAGÇÖs Circulatory System Devices
Panel Advisory Committee will meet to vote on the premarket
approval application of a minimally invasive technology to
treat specific cardiac arrhythmias. This technology, called
thermal (cold) cardiac ablation, is used by cardiologists to
treat specific arrhythmias of the heart that are difficult to
treat
March Madness For Biotech Traders
We all know what March symbolizes for die-hard college hoop
fans, and I include myself in this fanatical group.
However, March is also the beginning of a hectic three-month
stretch that offers great opportunity for biotech
traders. For the next three months, many biotech
companies will experience sentinel events surrounding their
potential
Biotech Postmortem:Â VaxGen and the AIDS Vaccine
VaxGen (VXGN) took investors for a wild ride yesterday after
the company released the United States clinical trial data of
its experimental AIDS vaccine — and what a ride it
was. The much-anticipated results of this closely
watched
Biotech Alert: VaxGen (VXGN) To Release AIDS Vaccine Data
Well, the moment of truth has arrived for VaxGenGÇÖs vaccine
(AIDSVAX) designed to prevent HIV infection and I truly
admire
Biotechs To Soothe The Heart
Since February has been designated GÇ£Heart Month,GÇ¥ I feel
obligated to shed some light on two biotechs with some very
exciting drugs in the developmental pipeline. There are
attractive qualities of these two companies that will garnish
a significant amount of investor attention as their drugs
approach
Exciting Week For Biotech
This has definitely not been a boring week for biotech.-áWith acquisitions, a high-profile meeting on new drugs to treat HIV infection, quarterly earnings reports, and management changes the sector has experienced some excitement.-áThe week started off with Johnson & JohnsonGÇÖs [JNJ|JNJ] announcement